The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
Open accessAbstract
BACKGROUND: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years. Most osteosarcoma epidemiology studies have been embedded in large analyses of all bone tumors or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival with direct comparisons among patients of all ages and ethnicities are not available. METHODS: Frequency, incidence, and survival rates for 3482 patients with osteosarcoma from the National Cancer Institute's population‐based Surveillance, Epidemiology, and End Results (SEER) Program between 1973 and 2004 were investigated by age (ages 0‐24 years, 25‐59 years, and 60 to ≥85 years), race, sex, pathology subtype, stage, and anatomic site. RESULTS: There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. There was a high percentage of osteosarcoma among patients with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage and did not improve significantly from 1984 to 2004. CONCLUSIONS: This comprehensive, population‐based description of osteosarcoma, identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteosarcoma is the most common primary malignant tumour of the bone.”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“higher rates of osteosarcoma have been observed in African American children and young adults in the USA than in white individuals 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence has a bimodal age distribution with a primary peak in adolescents and young adults and a second, smaller peak in the seventh and eighth decade of life 1”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“In the USA, osteosarcoma accounts for <1% of all new cancer diagnoses with ~1,000 new cases diagnosed per year, half of these cases occurring in children and adolescents 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Some studies suggested that the histological subtype of osteosarcoma can influence the degree of necrosis, with chondroblastic and telangiectatic subtypes having less necrosis but those differences have not translated into improvement in survival 1,118 .”
From Osteosarcoma (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
(1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,933
The international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2007) · Cancer · doi:10.1002/cncr.23169 · Cited by 644
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma
Damron, T. A., Ward, W. G., & Stewart, A. K. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e318059b8c9 · Cited by 530
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Bone Tumors: General Aspects and Data on 8,542 Cases
Spjut, H. J. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61914-4 · Cited by 455
Dahlin, D. C., & Coventry, M. B. (1967) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196749010-00008 · Cited by 453
Research works printed but not linked: 12
- 10.1002/1097-0142(19950101)75:1 <203::AID-CNCR2820751308>3.0.CO;2-V · DOI
- Dorfman HA, 1997, Bone Tumors
- Murray RO, 1975, A Textbook of Radiology, 109
- Hanson MR, 1982, Epidemiology of Cancer in the Young
- 10.1002/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C · DOI
- Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 2007, SEER Registries: Surveillance Research Program, National Cancer Institute
- Surveillance Research Program, 2007, National Cancer Institute SEER*Stat Software, version 6.3.6
- Day JC, 1996, Population Projections of the United States by Age, Sex, Race and Hispanic Origin, 1995 to 2050, US Bureau of the Census, Current Population Reports, P25‐1130
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 13 Regs Limited‐Use, November 2006 Submission (1992‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 9 Regs Limited‐Use, November 2006 Submission (1973‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 17 Regs Limited‐Use, November 2006 Submission (1973‐2004 varying)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Aegerter E, 1975, Orthopedic Disease
Cited by
Sorted by citations
Items 701–800 of 1,002
Qiu, J. Y., Zhang, Y., Hu, C., & Guo, Z. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4483 · Cited by 25
RetractedHeishima, K., Meuten, T., Yoshida, K., Mori, T., & Thamm, D. H. (2019) · BMC Veterinary Research · doi:10.1186/s12917-019-1776-1 · Cited by 25
Slade, A. D., Warneke, C. L., Hughes, D. P. M., Lally, P. A., Lally, K. P., Hayes-Jordan, A. A., & Austin, M. T. (2014) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2014.10.038 · Cited by 25
Zhou, Y., Lu, Q., Xu, J., Yan, R., Zhu, J., Xu, J., Jiang, X., Li, J., & Wu, F. (2017) · Oncotarget · doi:10.18632/oncotarget.20375 · Cited by 24
He, J., Wang, J., Wang, D., Dai, S., Yv, T., Chen, P., Ma, R., Diao, C., & Lv, G. (2014) · Endocrine · doi:10.1007/s12020-013-0050-8 · Cited by 24
Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma
Wang, C., Zhang, Y., Kong, W., Rong, X., Zhong, Z., Jiang, L., Chen, S., Li, C., Zhang, F., & Jiang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s471900 · Cited by 25
Immunotherapy of osteosarcoma based on immune microenvironment modulation
Lian, H., Zhang, J., Hou, S., Ma, S., Yu, J., Zhao, W., Zhao, D., & Zhang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498060 · Cited by 24
Jiang, C., Chen, H., Shao, L., & Dong, Y. (2014) · Medical Oncology · doi:10.1007/s12032-014-0050-4 · Cited by 24
Zhi, X., Wu, K., Yu, D., Wang, Y., Yu, Y., Yan, P., & Lv, G. (2016) · Europe PMC (PubMed Central) · Cited by 24
RetractedFan, S., Gao, X., Chen, P., & Li, X. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0236 · Cited by 24
Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability
Pierrevelcin, M., Fuchs, Q., Lhermitte, B., Messé, M., Guérin, É., Weingertner, N., Martin, S., Lelong-Rebel, I. H., Nazon, C., Dontenwill, M., et al. (2020) · Cells · doi:10.3390/cells9091998 · Cited by 28
Lu, S., Wang, Y., Liu, G., Wang, L., Wu, P., Li, Y., & Cheng, C. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02376-8 · Cited by 27
Danieau, G., Morice, S., Renault, S., Brion, R., Biteau, K., Amiaud, J., Cadé, M., Heymann, D., Lézot, F., Verrecchia, F., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14050421 · Cited by 26
Małek, A., Taciak, B., Dobruch‐Sobczak, K., Grzelak, A., Wójcik, M., Mieczkowski, J. B., Lechowski, R., & Zabielska-Koczywąs, K. A. (2021) · Molecules · doi:10.3390/molecules26123487 · Cited by 24
Li, S., Guo, R., Peng, Z., Quan, B., Hu, Y., Wang, Y., & Wang, Y. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110074 · Cited by 24
Growing Pains: The Need for Engineered Platforms to Study Growth Plate Biology
Tiffany, A. S., & Harley, B. A. C. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200471 · Cited by 25
Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas
Nie, J., Yang, T., Li, H., Li, S., Li, T., Ye, H., Lu, M., Chu, X., Zhong, G., Zhou, J., et al. (2022) · Cancer Science · doi:10.1111/cas.15521 · Cited by 25
Pierrevelcin, M., Flacher, V., Mueller, C. G., Vauchelles, R., Guérin, É., Lhermitte, B., Pencreach, E., Reisch, A., Muller, Q., Doumard, L., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200195 · Cited by 25
Hurkmans, E. G. E., Brand, A. C. A. M., Verdonschot, J. A. J., Loo, D. M. W. M. T., & Coenen, M. J. H. (2022) · BMC Cancer · doi:10.1186/s12885-022-10434-5 · Cited by 24
Weber, V., Stigler, R. G., Lutz, R., Kesting, M. R., & Weber, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1006622 · Cited by 24
Zhou, Y., ZHU, L. B., Peng, A. F., Wang, T. F., LONG, X. H., GAO, S., ZHOU, R. P., & Liu, Z. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2787 · Cited by 24
Xia, Y., Yang, L., Wang, Z., Guo, C., Zhang, C., Geng, Y., & Kong, L. (2015) · RSC Advances · doi:10.1039/c4ra14324h · Cited by 24
Zou, J., Zhang, W., & Li, X. (2017) · Calcified Tissue International · doi:10.1007/s00223-016-0231-6 · Cited by 24
David, E., Cagnol, S., Goujon, J., Egorov, M., Taurelle, J., Benesteau, C., Morandeau, L., Moal, C., Sicard, M., Pairel, S., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00210 · Cited by 24
Pathological and therapeutic aspects of matrix metalloproteinases: Implications in osteosarcoma
Tang, H., Tang, Z., Jiang, Y., Wei, W., & Lü, J. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13165 · Cited by 24
Iwai, T., Oebisu, N., Hoshi, M., Orita, K., Yamamoto, A., Hamamoto, S., Kageyama, K., & Nakamura, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-66934-6 · Cited by 24
Evenhuis, R. E., Acem, I., Rueten‐Budde, A. J., Karis, D. S. A., Fiocco, M. F., Dorleijn, D. M. J., Speetjens, F. M., Anninga, J., Gelderblom, H. A. J., & van de Sande, M. A. J. (2021) · Cancers · doi:10.3390/cancers13030486 · Cited by 24
Decreased RECQL5 correlated with disease progression of osteosarcoma
Wu, J., Zhi, L., Dai, X. J., Cai, Q., & Ma, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.114 · Cited by 24
Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk
Tang, Y., Wang, J., Xie, K., & Lan, C. (2016) · Scientific Reports · doi:10.1038/srep34607 · Cited by 24
Stress ulcers are common after aortic surgery. Endoscopic evaluation of prophylactic therapy.
Martin, L. F. (1994) · PubMed · Cited by 24
Osteoclasts in Osteosarcoma: Mechanisms, Interactions, and Therapeutic Prospects
Gao, Y.-M., Pei, Y., Zhao, F.-F., & Wang, L. (2023) · Cancer Management and Research · doi:10.2147/cmar.s431213 · Cited by 23
Biomaterials‐Boosted Immunotherapy for Osteosarcoma
Sun, C., Li, S., & Ding, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400864 · Cited by 25
Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy
Yu, Y., Li, K., Peng, Y., Zhang, Z., Pu, F., Shao, Z., & Wu, W. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101569 · Cited by 26
Zhang, Y., Kong, Q., Huang, Y., Wang, G., & Chang, K.-J. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2251 · Cited by 23
Castillo‐Tandazo, W., Mutsaers, A. J., & Walkley, C. R. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00534-w · Cited by 23
Tripathi, H. S., Pandey, G. C., Dubey, A. K., Shaw, S. K., Prasad, N. K., Singh, S. P., & Rath, C. (2020) · Advanced Engineering Materials · doi:10.1002/adem.202000275 · Cited by 23
Wagner, M., Breusch, S. J., Ewerbeck, V., Aldinger, P. R., Rudert, M., Holzapfel, B. M., Günther, K., Gotterbarm, T., Kirschner, P., Halder, A. M., et al. (2011) · Springer eBooks · doi:10.1007/978-3-642-14646-6_7 · Cited by 23
Xu, Y., Qi, J., Sun, W., Zhong, W., & Wu, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.897641 · Cited by 23
Lai, H.-T., Naumova, N., Marchais, A., Gaspar, N., Geoerger, B., & Brenner, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.948097 · Cited by 23
Tarone, L., Giacobino, D., Camerino, M., Maniscalco, L., Iussich, S., Parisi, L., Giovannini, G., Dentini, A., Bolli, E., Quaglino, E., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.004 · Cited by 23
Mini-bones: miniaturized bone in vitro models
Fois, M. G., van Griensven, M., Giselbrecht, S., Habibović, P., Truckenmüller, R. K., & Birgani, Z. N. T. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.01.004 · Cited by 23
Alcaide, M. J., Ramírez‐Santillán, C., Feito, M. J., Matesanz, M. C., Ruiz‐Hernández, E., Arcos, D., Vallet‐Regí, M., & Portolés, M. T. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33229 · Cited by 23
miR-26a suppresses osteosarcoma migration and invasion by directly targeting HMGA1
Liu, J., Bo, M., Wang, Y., Shi, C., Mi, X., Lu, Y., & Yu, P. (2018) · Oncology Letters · doi:10.3892/ol.2018.8359 · Cited by 23
miR-202-5p inhibits the migration and invasion of osteosarcoma cells by targeting ROCK1
Li, C., Ma, D., Yang, J., Lin, X., & Chen, B. (2018) · Oncology Letters · doi:10.3892/ol.2018.8694 · Cited by 24
Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line
Kito, F., Oyama, R., Sakumoto, M., Takahashi, M., Shiozawa, K., Qiao, Z., Sakamoto, H., Hirose, T., Setsu, N., Yoshida, A., et al. (2018) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-018-0274-2 · Cited by 23
Role of miR‐142 in the pathogenesis of osteosarcoma and its potential as therapeutic approach
Shabani, P., Izadpanah, S., Aghebati‐Maleki, A., Baghbani, E., Baghbanzadeh, A., Fotouhi, A., Bakhshinejad, B., Maleki, L. A., & Baradaran, B. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27857 · Cited by 23
Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma
Ferrari, A., Gasparini, P., Gill, J. B., & Gorlick, R. G. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000337 · Cited by 23
Shi, J., & Hao, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.114 · Cited by 23
Daqian, W., Wang, C., Xinhua, Q., Ai, S., & Kerong, D. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.05.008 · Cited by 23
Survival analysis of elderly patients with osteosarcoma
Imura, Y., Takenaka, S., Kakunaga, S., Nakai, T., Wakamatsu, T., Outani, H., Tanaka, T., Tamiya, H., Oshima, K., Hamada, K., et al. (2019) · International Orthopaedics · doi:10.1007/s00264-019-04332-y · Cited by 23
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
Hattinger, C. M., Patrizio, M. P., Luppi, S., & Serra, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134659 · Cited by 23
Pearson, A. D., Gaspar, N., Janeway, K., Campbell-Hewson, Q., Lawlor, E. R., Copland, C., Karres, D., Norga, K., Benzaghou, F., Weiner, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.008 · Cited by 22
Jo, Y., Sarkar, N., & Bose, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02210a · Cited by 22
Serum miR-300 as a diagnostic and prognostic biomarker in osteosarcoma
Liu, J.-D., Xin, Q., Tao, C., Sun, P., Xu, P., Wu, B., Qu, L., & Li, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5214 · Cited by 22
RSF1 functions as an oncogene in osteosarcoma and is regulated by XIST/miR-193a-3p axis
Wu, D., Nie, X., Ma, C., Liu, X.-H., Liang, X., An, Y., Zhao, B., & Wu, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.068 · Cited by 22
MicroRNA-1301 inhibits migration and invasion of osteosarcoma cells by targeting BCL9
Wang, L., Hu, K., & Chao, Y. (2018) · Gene · doi:10.1016/j.gene.2018.08.078 · Cited by 22
Ramkumar, D. B., Ramkumar, N., Miller, B. J., & Henderson, E. R. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.10.013 · Cited by 22
Long non‑coding RNA MIAT competitively binds miR‑150‑5p to regulate ZEB1 expression in osteosarcoma
Jin, H., Jin, X., Chai, W., Yin, Z., Li, Y., Dong, F., & Wang, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.9671 · Cited by 22
Liu, Y., Hong, Z., Chen, P., Wang, J., Zhou, Y., & Huang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10617 · Cited by 22
Gong, H., Tao, Y., Mao, X., Song, D., You, D., & Ni, J. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4287 · Cited by 22
Role of microRNA‑33a in malignant cells (Review)
Gao, C., Wei, J., Tang, T., & Huang, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11835 · Cited by 22
Thébault, É., Piperno-Neumann, S., Tran, D., Pacquement, H., Marec‐Bérard, P., Lervat, C., Castex, M., Cleirec, M., Bompas, E., Vannier, J., et al. (2021) · Cancers · doi:10.3390/cancers13071683 · Cited by 22
Kong, H., Yu, W., Chen, Z., Li, H., Ye, G., Hong, J., Xie, Z., Chen, K., Wu, Y., & Shen, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02320-0 · Cited by 22
Tan, J., Yang, B., Zhong, H., Luo, M., Su, Z., Xie, C. L., Shi, M., Sun, C., & Lin, L. (2023) · Biomarker Research · doi:10.1186/s40364-022-00442-9 · Cited by 22
Sun, Y., Wu, Y., Li, W., Kong, Z., & Zou, X. (2015) · PubMed Central · Cited by 22
The Role of Inflammation in Sarcoma
Radons, J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_11 · Cited by 22
Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis
Bai, X., Meng, H., Ma, L., & Guo, A. (2014) · Oncology Letters · doi:10.3892/ol.2014.2791 · Cited by 22
Changing prognostic factors in osteosarcoma: analysis of 381 cases from two institutions
Xing, D., Qasem, S. A., Owusu, K., Zhang, K., Siegal, G. P., & Wei, S. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.010 · Cited by 22
Osteosarcoma in Patients with Rothmund–Thomson Syndrome
Zils, K., Klingebiel, T. E., Behnisch, W., Muller, H. L., Schlegel, P., Fruehwald, M., Suttorp, M., Simon, T., Werner, M., & Bielack, S. (2014) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2014.987939 · Cited by 22
Genetic variation at chromosome 8q24 in osteosarcoma cases and controls
Mirabello, L. J., Berndt, S. I., Seratti, G. F., Burdett, L. A., Yeager, M., Chowdhury, S., Teshome, K., Uzoka, A., Douglass, C. W., Hayes, R. B., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq117 · Cited by 23
Self-citation60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center
Rodriguez, M. A., Walters, R. S., & Burke, T. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5197-6 · Cited by 22
IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
Shekhar, T. M., Miles, M. A., Gupte, A., Taylor, S., Tascone, B., Walkley, C. R., & Hawkins, C. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8980 · Cited by 22
An Update into the Application of Nanotechnology in Bone Healing
Brannigan, K., & Griffin, M. (2016) · The Open Orthopaedics Journal · doi:10.2174/1874325001610010808 · Cited by 22
Chen, P., Gu, W.-L., Gong, M.-Z., Wang, J., & Li, D.-Q. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.22 · Cited by 22
Schlegel, M., Zeumer, M., Prodinger, P. M., Woertler, K., Steinborn, M., von Eisenhart‐Rothe, R., Burdach, S. E. G., Rechl, H., & von Luettichau, I. (2018) · Oncology · doi:10.1159/000487142 · Cited by 22
Xie, B., Li, Y., Zhao, R., Xu, Y., Wu, Y., Wang, J., Xia, D., Han, W., & Chen, D. (2018) · BioMed Research International · doi:10.1155/2018/4761064 · Cited by 22
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
Holme, H., Gulati, A., Brough, R., Fleuren, E. D. G., Bajrami, I., Campbell, J., Chong, I. Y.-S., Costa-Cabral, S., Elliott, R. J. R., Fenton, T. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29043-z · Cited by 23
Development and validation of a nomogram for osteosarcoma-specific survival
Zhang, J., Yang, J., Wang, H., Pan, Z., Yan, X., Hu, C., Li, Y., & Lyu, J. (2019) · Medicine · doi:10.1097/md.0000000000015988 · Cited by 22
A propensity‐score matched analysis of limb salvage vs amputation for osteosarcoma
Traven, S. A., Brinton, D. L., Walton, Z. J., & Leddy, L. R. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25701 · Cited by 22
Hsieh, M.-H., Yang, J., Lin, R.-C., Hsieh, Y., Yang, S., Chang, H., & Lu, K. (2020) · Molecules · doi:10.3390/molecules25020326 · Cited by 22
Huang, J., Xu, Y., & Lin, F. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15716 · Cited by 22
Fu, P., Shi, Y., Chen, G., Fan, Y., Gu, Y., & Gao, Z. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820947701 · Cited by 22
Profile of Paediatric Malignancies: A Five Year Study
Jabeen, S., Haque, M., Islam, M., & Talukder, M. H. (1970) · Journal of Dhaka Medical College · doi:10.3329/jdmc.v19i1.6249 · Cited by 22
Ding, L., Wu, L., Cao, Y., Wang, H., Li, D., Chen, W., Huang, P., & Jiang, Z. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04950-2 · Cited by 21
Zhou, D., Yang, X., Li, H., Yang, Y., Zhen-jun, Z., & Wu, N. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000240 · Cited by 21
RETRACTED: Knockdown of long non-coding RNA HOXD-AS1 inhibits the progression of osteosarcoma
Qu, Y., Zheng, S., Kang, M., Dong, R., Zhou, H., Zhao, D., & Zhao, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.024 · Cited by 21
RetractedA nomogram for determining the disease-specific survival in Ewing sarcoma: a population study
Zhang, J., Pan, Z., Yang, J., Yan, X., Li, Y., & Lyu, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5893-9 · Cited by 21
CDC20 and its downstream genes: potential prognosis factors of osteosarcoma
Wu, M.-S., Ma, Q., Liu, D., Li, X., Deng, L., Li, N., Shen, J., Zhao, Z., & Chen, J. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01500-3 · Cited by 21
Zhu, X., Lu, K., Cao, L., Hu, Y., Yin, Y., & Cai, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s270825 · Cited by 21
Liang, C., Yu, X.-J., Xiong, N., Zhang, Z.-C., Sun, Z., & Dong, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615146 · Cited by 14
Prognostic Signature of Osteosarcoma Based on 14 Autophagy-Related Genes
Wei, Q., Yan, Q., Lv, M., Song, D., Wang, X., & Tian, K. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609782 · Cited by 22
Allen, T. A., Cullen, M. M., Hawkey, N. M., Mochizuki, H., Nguyễn, L., Schechter, E. G., Borst, L. B., Yoder, J. A., Freedman, J. A., Patierno, S. R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641187 · Cited by 21
Letko, A., Minor, K. M., Norton, E. M., Marinescu, V. D., Drögemüller, M., Ivansson, E. L., Megquier, K., Noh, H. J., Starkey, M., Friedenberg, S. G., et al. (2021) · Genes · doi:10.3390/genes12121964 · Cited by 21
Martínez-Vélez, N., Laspidea, V., Zalacain, M., Labiano, S., García-Moure, M., Puigdelloses, M., Marrodan, L., Gonzalez-Huarriz, M., Herrador, G., de la Nava, D., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0565 · Cited by 21
Wang, B., Zhou, Y., Zhang, P., Li, J., & Lu, X. (2023) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x23500593 · Cited by 21
Jiang, Y., Liu, Y., Zhang, Y., Ouyang, J., Yang, F., Li, S., Wang, J., Zhang, C., Tan, L., Zhong, J. M., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110792 · Cited by 21
Song, D., Ni, J., Xie, H., Ding, M., & Wang, J. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1571 · Cited by 21
Cai, X., & Yang, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1124-8 · Cited by 21
Fluoride exposure in public drinking water and childhood and adolescent osteosarcoma in Texas
Archer, N. P., Napier, T. S., & Villanacci, J. F. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0759-9 · Cited by 21
Zhang, Q., Lv, L. Y., Li, B., Zhang, J., & Wei, F. (2015) · Genetics and Molecular Research · doi:10.4238/2015.september.22.17 · Cited by 21
Metadata
- Authors
- Mirabello, L., Troisi, R. J., & Savage, S. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Savage, Sharon A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 115
- Issue
- 7
- Pages
- 1531-1543
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2813207
- OpenAlex
- W1988325237
- Cited by
- 2,199
- References
- 52
- Citations by year
- 2026: 114 · 2025: 138 · 2024: 166 · 2023: 167 · 2022: 161 · 2021: 194 · 2020: 201 · 2019: 162 · 2018: 172 · 2017: 142 · 2016: 151 · 2015: 129 · 2014: 106 · 2013: 72 · 2012: 52
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010142)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- osteosarcoma, incidence, survival rate, age differences, Paget disease, secondary malignancies, elderly patients, disease stage, SEER, bone tumors, mortality trends
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Bone Neoplasms, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Osteosarcoma, Sex Factors, Survival Rate, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
